Last updated: February 19, 2026
Several pharmaceutical suppliers produce sorafenib tosylate, a kinase inhibitor approved for hepatocellular carcinoma, renal cell carcinoma, and thyroid carcinoma. The following list summarizes key global suppliers, their manufacturing status, and distribution scope.
Major Suppliers
| Supplier Name |
Manufacturing Status |
Regions Served |
Notes |
| Bayer Pharma AG |
Produces and markets under brand name Nexavar |
Global, especially North America, Europe, Asia |
Original patent holder; licensed manufacturing to others. |
| Dr. Reddy's Laboratories |
Manufactures generic formulations |
India, Latin America, Africa |
Authorized generic production; FDA-approved formulations. |
| Cipla Ltd. |
Produces generic sorafenib formulations |
India, Middle East, Africa |
Focused on emerging markets. |
| Mylan (now part of Viatris) |
Manufactures generic versions |
North America, Europe, Asia |
Complies with local regulatory approvals. |
| Aurobindo Pharma |
Produces sorafenib tosylate** |
India, USA |
GMP-compliant manufacturing facilities. |
| Shanghai Fosun Pharmaceutical |
Produces under local licensing agreements |
China, Asia-Pacific |
Licenses from original patent holders or local development. |
Manufacturing and Licensing Trends
- Original patent holder: Bayer holds the patent and markets under the brand name Nexavar.[1]
- Patent expiration: Patents expired or are nearing expiry in multiple jurisdictions, leading to increased generic production.[2]
- Generic proliferation: Over 20 manufacturers globally produce sorafenib tosylate, with primary focus on emerging markets.
Regulatory Approvals and Market Access
- United States (FDA): Multiple generics approved since patent expiry, including those from Dr. Reddy's, Mylan, and Aurobindo.
- European Medicines Agency (EMA): Approved generic manufacturers, subject to regional licensing.
- China: Several local manufacturers produce sorafenib formulations, often under local licensing agreements with Bayer or independently.
Supply Chain Considerations
- Active Pharmaceutical Ingredient (API) supply: API manufacturing concentrated in China and India, with a growing number of certified facilities.[3]
- Formulation manufacturing: Primarily based in India, China, and established generic markets.
- Distribution scope: Widely available in North America, Europe, India, and parts of Asia and Africa via regional partners.
Summary
- Bayer remains the primary patent holder and supplier for branded sorafenib tosylate.
- Generics from Indian and Chinese manufacturers dominate the global supply post-patent expiry.
- Several approved suppliers exist across high-growth markets, primarily focusing on API manufacturing in China and India, and formulation assembly in India, South Asia, and North America.
- Market access is facilitated through regional licensing agreements, regulatory approvals, and manufacturing certifications.
Key Takeaways
- Bayer's Nexavar is the originator; global generic production stems from patent expiration.
- Multiple suppliers, predominantly in India and China, supply sorafenib tosylate.
- Supply chain is concentrated in API production in Asia, with formulation manufacturing spread across emerging markets.
- Regulatory approvals vary by region, enabling widespread access to generic versions.
- This landscape is expected to evolve with patent expirations and regional licensing strategies.
FAQs
1. Who holds the original patent to sorafenib tosylate?
Bayer Pharma AG owns the original patent and markets it under the brand name Nexavar.
2. When did patent expiry occur in key markets?
Patent expiry dates vary by jurisdiction, with patents generally expiring between 2017 and 2022 in major markets like the U.S. and Europe.
3. Which companies supply generic sorafenib tosylate?
Suppliers include Dr. Reddy’s Laboratories, Mylan, Aurobindo Pharma, Cipla, and local manufacturers in China and India.
4. Are there regional differences in supply?
Yes. In North America and Europe, supply predominantly comes from licensed generics. In China and India, multiple local manufacturers produce sorafenib formulations.
5. What is the typical supply chain flow for sorafenib tosylate?
API is mainly produced in China and India, then shipped to formulation plants in India, China, and other regions for packaging and distribution.
References
[1] Bayer AG. (n.d.). Nexavar (Sorafenib) Product Information. Bayer.
[2] U.S. Food and Drug Administration. (2022). Approved Drug Products: Patent Expiration Dates. FDA.
[3] IMS Health. (2021). API Manufacturing in China and India. IMS.
